Our Partners

Therapeutic Programs

We are early in our journey but we are making effective strides for rare disease and vision loss. Newly launched this year, our Usher Syndrome gene therapy for patients with vision loss caused by USH1C mutations is the newest program to join the Odylia portfolio. Staying true to our mission and core values, the USH1C program was developed in partnership with a community of experts and two different patient groups focused on developing treatments for Usher Syndrome. USH1C joins the Odylia portfolio alongside the RPGRIP1 program, a gene therapy to treat patients with vision loss caused by mutations in RPGRIP1. PTC Therapeutics licensed the RPGRIP1 gene therapy program in June of 2019.

Our Partners

Aldevron Partner of Odylia Therapeutics Logo
Lonza Partner of Odylia Therapeutics Logo
Roche Partner of Odylia Therapeutics Logo
Nightstar Therapeutics Logo
arm_footer_logo-1
Usher 2020 foundation logo
Faber_Law_Logo_1
Mintz Law Firm Partner of Odylia Therapeutics Logo
Hester Designs Partner of Odylia Therapeutics Logo
Massachusetts Eye and Ear logo
PTC_Therapuetics

Questions? We’re here to help!